Predicted Trait | |
Reported Trait | Heart failure |
Mapped Trait(s) | heart failure (EFO_0003144) |
Score Construction | |
PGS Name | HF_PRS |
Development Method | |
Name | Genome-wide significant SNPs |
Parameters | p<5E-08 |
Variants | |
Original Genome Build | NR |
Number of Variants | 12 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000766 |
Citation (link to publication) | Türkmen D et al. Pharmacogenomics J (2024) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 977,323 individuals (100%) |
PGS Evaluation | European: 100% 1 Sample Sets |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST009541 Europe PMC: 31919418 |
977,323 individuals | European | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM023066 | PSS012106| European Ancestry| 32,360 individuals |
PGP000766 | Türkmen D et al. Pharmacogenomics J (2024) |
Reported Trait: Incident heart failure | HR: 1.14 [1.09, 1.19] | — | — | sex, age at first prescription and genetic principal components 1 to 10 | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS012106 | — | — | 32,360 individuals, 54.4 % Male samples |
— | European | — | UKB | — |